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ABSTRACT
Background. Elderly patients who undergo esophagec-
tomy for cancer often have a high prevalence of coexisting
diseases, which may adversely affect their postoperative
course. We determined the relationship of advanced age
(i.e., C70 years) with outcome and evaluated age as a
selection criterion for surgery.
Methods. Between January 1991 and January 2007, we
performed a curative-intent extended transthoracic esopha-
gectomy in 234 patients with cancer of the esophagus.
Patientsweredividedintotwoagegroups:\70 years(group
I; 170 patients) and C70 years (group II; 64 patients).
Results. Both groups were comparable regarding comor-
bidity (American Society of Anesthesiologists classiﬁ-
cation), and tumor and surgical characteristics. The overall
in-hospital mortality rate was 6.2% (group I, 5%, vs. group
II, 11%, P = 0.09). Advanced age was not a prognostic
factor for developing postoperative complications (odds
ratio, 1.578; 95% conﬁdence interval, 0.857–2.904;
P = 0.143). The overall number of complications was
equal with 58% in group I vs. 69% in group II (P = 0.142).
Moreover, the occurrence of complications in elderly
patients did not inﬂuence survival (P = 0.174). Recur-
rences developed more in patients \70 years (58% vs.
42%, P = 0.028). The overall 5-year survival was 35%,
and, when included, postoperative mortality was 33% in
both groups (P = 0.676).The presence of comorbidity was
an independent prognostic factor for survival (P = 0.002).
Conclusions. Advanced age (C70 years) has minor inﬂu-
ence on postoperative course, recurrent disease, and
survival in patients who underwent an extended esopha-
gectomy. Age alone is not a prognostic indicator for
survival. We propose that a radical resection should not be
withheld in elderly patients with limited frailty and
comorbidity.
Esophageal cancer predominantly occurs in the last
decades of life, with a median age of [60 years.
1,2
Although important improvements have been achieved in
the multimodality treatment of these tumors, surgery
remains the primary curative option.
3,4 Esophagectomy is a
high-risk procedure with serious postoperative complica-
tions and a reported mortality rate ranging from 2 to
6%.
1,3,5 Moreover, esophageal cancer patients often have
considerable risk factors for major surgery, including
obesity and pulmonary and cardiovascular diseases.
6,7
Besides the increasing incidence of esophageal adeno-
carcinoma, the rising life expectancy in the general
population is responsible for a relatively large number of
elderly patients with esophageal cancer.
1 Elderly patients
who undergo esophagectomy often have a high prevalence
of comorbidity and frailty, suggesting a negative effect on
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8–12 Therefore, sur-
geons are in general more reluctant to perform major
surgery in these elderly patients.
There is a lack of evidence regarding the appropriate
surgical treatment of esophageal cancer in the elderly
population. Some authors propose a transhiatal procedure
for better short-term outcome with less morbidity, while
others perform a standard extended esophagectomy with
a two-ﬁeld lymphadenectomy in all patients with
esophageal carcinoma to achieve maximal oncological
control and minimizing the chance of recurrent
disease.
13–15
In the absence of an established deﬁnition of elderly
patients regarding high-risk surgery, most studies deﬁned
advanced age as C70 years.
8,10,11,16–22
We report the results from an experienced high-volume
single center in elderly patients who underwent extended
transthoracic esophagectomy with two-ﬁeld lymphadenec-
tomy for cancer of the esophagus. We performed several
analyses to determine the effect of advanced age on
comorbidity, postoperative course, recurrent disease, and
survival. We evaluated age as a selection criterion for
surgery and make recommendations for the optimal treat-
ment policy in elderly patients.
PATIENTS AND METHODS
Patient Characteristics and Treatment
Between January 1991 and January 2007, a total of 234
patients with cancer of the esophagus or gastroesophageal
junction underwent esophagectomy with curative intent.
All patients underwent surgery in the same high-volume
university medical center by the same surgical group,
which consisted of two surgeons. All included patients
were medically ﬁt enough to undergo surgery. Patients who
underwent neoadjuvant treatment in a nationwide trial,
starting from 2006 on, were excluded for evaluation to
prevent treatment bias (n = 6). Patients who underwent
exploration for unforeseen extension of disease were
excluded.
Comorbidity
Comorbidity was determined by the American Society
of Anesthesiologists (ASA) physical status classiﬁcation.
ASA is a readily available and widely accepted way to
stratify surgical patients according to their perioperative
risk and varies between ASA class 1 (very good condi-
tion) and ASA class 5 (moribund patient).
23 ASA class
was assigned by the anesthesiologist after completing
a structured review of physical status just before
esophagectomy.
Preoperative Workup
Patients were considered for curative esophagectomy
after a complete preoperative workup, which included
physical examination, standard laboratory tests, digestive
endoscopy, histopathological examination of biopsy sam-
ples, and detailed preoperative risk assessments. Staging of
the tumors was performed by endoscopic ultrasound with
ﬁne-needle aspiration and computed tomography (CT) of
the chest, abdomen, and cervical region. In all patients
newly diagnosed with T3–4 or N1 esophageal cancer, a
18F-ﬂuoro-2-deoxy-D-glucose positron emission tomogra-
phy (PET) scan was performed. In case of anatomical
difﬁculties on PET assessment, a PET/CT fusion scan was
performed. Before surgery, all patients were discussed in
multidisciplinary meetings.
Surgery
An extended esophageal resection was performed in all
patients. This procedure consisted of a subtotal esophageal
resection through a left thoracolaparotomy with intratho-
racic anastomoses for the distal and gastroesophageal
cancers or through a right thoraco-mid laparotomy with
cervical anastomoses for the higher intrathoracic tumors.
Both were combined with a two-ﬁeld lymphadenectomy of
nodes at the celiac trunk, upper border of the pancreas,
para-aortic region, and mediastinal nodes.
Histology
All resected specimens and lymph nodes were examined
according to standard procedures. Tumor stage and grade
were classiﬁed according to the 6th edition of the tumor,
node, and metastasis system and the residual tumor (R)
classiﬁcation of the International Union Against Cancer
and the American Joint Committee on Cancer.
24,25 Ade-
nocarcinomas observed on hematoxylin and eosin–stained
samples were conﬁrmed in all cases by keratin staining
(immunohistochemical analysis).
Mortality and Complications
Postoperative mortality was deﬁned as any death within
the same hospital admission and all deaths within the ﬁrst
90 days after surgery. A separate calculation was made of
only 90-day mortality (without in-hospital deaths after
90 days) to compare these ﬁgures with the data in litera-
ture. Major complications were divided into pulmonary
complications: respiratory insufﬁciency (prolonged need
for mechanical ventilation), acute respiratory distress syn-
drome (acute and persistent lung inﬂammation with
increased vascular permeability and severe hypoxemia),
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culture, including bronchoalveolar lavage), atelectasis
(collapse of lung lobe on x-ray with hypoxemia for which
intensive physiotherapy or bronchoscopy was needed),
pleural effusion (ﬂuid seen on x-ray for which drainage
was necessary because of hypoxemia), empyema (positive
culture or positive ﬂuid) and pulmonary embolism (diag-
nosed by CT); cardiac complications; arrhythmia
(diagnosed on electrocardiogram) and myocardial infarc-
tion (diagnosed on electrocardiogram and positive
laboratory tests); and other major complications; reblee-
ding (bleeding requiring transfusion or reoperation),
subphrenic abscess and/or intra-abdominal abscess (CT,
drainage, and positive culture), systemic inﬂammatory
response syndrome (SIRS; deregulated host with inﬂam-
matory response with absent infection: temperature[38.5
or\35C, heart rate[90 beats/min, respiratory rate[20
breaths/min or PaCO2\32 mm Hg and white blood
cells[12,000 cells/mm
3), sepsis (the clinical signs of
SIRS, but with culture-proven infection or an infection
identiﬁed by visual inspection), anastomotic leakage (CT
with enteral contrast and amylase in the pleural ﬂuid),
chylothorax (chyle deﬁned by measuring triglycerides),
renal failure (increasing creatinine and oliguria for which
renal replacement therapy was necessary), liver failure
(increasing bilirubin, liver enzymes, lactate, and pro-
thrombin time), and deep venous thrombosis (of the distal
or proximal lower extremity) and ileus (absence of peri-
stalsis with gastric retention and no defecation, conﬁrmed
with abdominal X-ray). Minor complications were deﬁned
as wound infections (positive wound culture with pus),
wound dehiscence (spontaneous opening of the fascia) and
urinary tract infections (sepsis, urinary leucocytes, and 10
5
bacteria/ml in urine). Infectious complications were
subdivided into septic complications (sepsis) and intra-
abdominal or subphrenic abscess eventually with anasto-
motic leakage, empyema, pneumonia, severe wound
infections, and urinary tract infections. The use of antibi-
otics and inotropes was scored during the postoperative
period. The operation room time, intensive care unit (ICU)
length of stay, and hospital length of stay were measured
for comparison.
Follow-up
All medical follow-up data were collected prospectively
in a patient research database. Patients were seen in the
outpatient department every 3 months for the ﬁrst postop-
erative year, every 6 months for the next year, and then
annually for 10 years. Data of deceased patients were
collected by consulting the general practitioners and the
Comprehensive Cancer Center, North Netherlands. Follow-
up was measured in months from the time of operation
until death (survival time) or end of follow-up with a
minimum of 2 years.
For the calculation of long-term cancer-speciﬁc sur-
vival, patients without postoperative mortality were
selected (n = 219), and only cancer-related cause of death
was scored. Death by any other cause was scored as end of
follow-up. For all other survival calculations, postoperative
mortality was included in the survival curves.
Recurrent disease was deﬁned as locoregional recur-
rence or distant metastases in the follow-up period,
determined by any cytologic or histologic proof, unequiv-
ocal radiologic suspicion (CT, magnetic resonance
imaging, PET, bone scan, and ultrasound), and/or obvious
clinical manifestations.
The follow-up was ascertained in February 2009 and
was complete for all included patients.
Deﬁnitions and Statistical Analyses
For calculations, ‘‘elderly’’ was deﬁned as a patient
C70 years of age, as generally used in the litera-
ture.
8,10,11,16–22 Therefore, we discriminated between group
I, \70 years, and group II, C70 years, independently of
other factors.
Variables were reﬂected as frequencies with means and/
or median with percentages. Continuous variables were
compared by the t-test, and the v
2 test was used for com-
parison of categorical variables. Survival and recurrence
rates were calculated by the Kaplan-Meier method and the
log rank test. Survival calculations included postoperative
mortality, except for the cancer-speciﬁc survival. Prog-
nostic factors for survival were calculated with Cox
regression univariate and multivariate analyses. Univariate
and multivariate logistic and linear regression analysis
were used for calculating if advanced age was inﬂuencing
the occurrence of comorbidity and complications; the
group of complications (cardiac, pulmonary, and infectious
complications) were calculated as well as individual
complications. Multivariate analysis was performed by
incorporating factors as covariates with a P value of B0.1
on univariate analysis.
For all calculations, a P value of\0.05 was considered
to be signiﬁcant. Statistical computations and ﬁguring were
all performed by SPSS software, version 16.0 (SPSS,
Chicago, IL).
RESULTS
Patients Characteristics
The study population consisted of 234 consecutive
patients, 196 men (84%) and 38 women (16%). The mean
1574 B. B. Pultrum et al.age at operation was 63 years, with a range of 28 to
82 years. Group I (\70 years of age) consisted of 170
patients (73%) and group II (C70 years of age) of 64
patients (27%). Patients and tumor characteristics are
summarized in Table 1. Surgical characteristics such as
year of surgery (P = 0.4) and type of resection (P = 0.9)
were similar in both groups. Stage of disease was not sta-
tistically different in both groups (P = 0.148), although
more advanced disease seemed to occur in the younger
patients (Table 1).
Comorbidity was not signiﬁcantly different in both
groups: 65 patients (38%) with comorbidity in group I
versus 32 patients (50%) in group II (P = 0.104). ASA
class did not differ between the two groups (P = 0.136).
Mortality and Comorbidity
Postoperative mortality (deﬁned as within 90 days of
surgery and within-hospital admission) was 6.2% (15
patients), 8 patients (5%) in group I versus 7 patients (11%)
in group II (P = 0.09). The 90-day mortality alone was
4.7% (11 patients), with 5 patients (3%) in group I and 6
patients (9%) in group II (P = 0.08). Of the 15 patients
who died after surgery, 10 (67%) had more than one
comorbidity (P = 0.041). Four patients had a history of
myocardial infarction and hypertension; one patient had
diabetes with myocardial infarction; two patients had dia-
betes with hypertension; one patient had chronic
obstructive pulmonary disease with transient ischemic
attack; and two patients had a transient ischemic attack
with hypertension. Only cardiovascular comorbidity in the
elderly subgroup (n = 24; 38%) had a negative effect on
postoperative mortality (P = 0.043).
Complications
Ninety-nine patients (58%) in group I and 44 patients
(69%) in group II developed postoperative complications,
which was not statistically different between both groups
(P = 0.142). Pulmonary complications occurred in 72
patients (42%) in group I versus 36 patients (56%;
P = 0.06) in group II, respectively (Table 2). Respiratory
insufﬁciency was the most frequent complication and
occurred more in the elderly patients (25 vs. 41%;
P = 0.017). Other major pulmonary complications, ate-
lectasis (14% vs. 28%; P = 0.009) and pleural effusion
TABLE 1 Characteristics of
elderly patients with esophageal
cancer (n = 234) and of tumor
GEJ gastroesophageal junction,
COPD chronic obstructive
pulmonary disease, TIA/CVA
transient ischemic attack/
cerebral vascular accident
Variable Group I
(age\70)
(N = 170)
Group II
(age C 70)
(N = 64)
P
value
Mean age (y) 58.9 74.5
Sex (M/F) 144/26 52/12 0.524
Histology, n (%)
Adenocarcinoma 145 (85) 56 (87) 0.666
Squamous-cell
carcinoma
25 (15) 8 (13)
Localization, n (%)
Midesophagus 14 (8) 4 (6) 0.371
Distal esophagus 102 (60) 36 (56)
GEJ 54 (32) 24 (38)
Tumor stage, n (%)
I 17 (10) 11 (17) 0.148
IIa 46 (27) 17 (26)
IIb 16 (9) 8 (13)
III 80 (47) 25 (39)
IVa 11 (7) 3 (5)
Comorbidity, n (%)
Diabetes mellitus 17 (10) 8 (13) 0.582
Hypertension 28 (16) 15 (23) 0.221
Angina pectoris 12 (7) 5 (8) 0.843
Heart failure 1 (1) 2 (3) 0.125
Myocardial infarction 17 (10) 7 (11) 0.833
COPD 16 (9) 6 (9) 0.993
TIA/CVA 7 (4) 6 (9) 0.118
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group II. Cardiac complications, primarily consisting of
arrhythmias, occurred in 27 patients (16%) versus 24
patients (38%) in group II (P = 0.001). Pneumonia was the
most common infectious complication in 43 patients
(18%), 16% in group I and 23% in group II (P = 0.221).
There were no differences between infectious and nonin-
fectious complications between the two groups (P = 0.5).
Four abscesses developed in the elderly group (6%).
The postoperative use of antibiotics and inotropes did
not differ statistically between both age groups (P = 0.4
and P = 0.13).
In logistic regression analysis, age C70 years was not a
prognostic factor for development of postoperative
complications (odds ratio [OR], 1.578; 95% conﬁdence
interval [95% CI], 0.857 to 2.904; P = 0.143). For cardiac
complications (OR, 3.178; 95% CI, 1.655 to 6.100;
P = 0.001) and pulmonary complications (OR, 1.750; 95%
CI, 0.980 to 3.126; P = 0.05) as a group, age C70 years
was a prognostic factor (Table 3).
There was a higher rate of complications in the patients
with comorbidity; 69 (71%) of the 97 patients who had
comorbidity developed one or multiple postoperative com-
plications (P = 0.008). However, of the 143 patients who
had complications, only 69 (48%) had preoperative ﬁxed
comorbidity. In logistic regression analysis, comorbidity
was a prognostic factor for developing postoperative com-
plications (OR, 2.098; 95% CI, 1.207 to 3.647; P = 0.009)
TABLE 2 Complications in
elderly patients with esophageal
cancer (n = 234)
ARDS acute respiratory distress
syndrome, SIRS systemic
inﬂammatory response
syndrome, ICU intensive care
unit
Bold values are signiﬁcant
(P B 0.005)
Variable Group I (age\70), n (%)
(N = 170)
Group II (age C 70), n (%)
(N = 64)
P
value
Overall complications 99 (58) 44 (69) 0.142
Pulmonary complications 72 (42) 36 (56) 0.058
Respiratory insufﬁciency 42 (25) 26 (41) 0.017
ARDS 4 (2) 3 (5) 0.351
Pneumonia 28 (16) 15 (23) 0.221
Atelectasis 23 (14) 18 (28) 0.009
Pleural effusion 25 (15) 17 (27) 0.036
Empyema 16 (9) 9 (14) 0.306
Pulmonary embolism 4 (2) 3 (5) 0.351
Cardiac complications 27 (16) 24 (38) \0.001
Arrhythmia 27 (16) 23 (36) 0.001
Myocardial infarction 2 (1) 1 (2) 0.815
Other major complications
Rebleeding 4 (2) 4 (6) 0.144
Subphrenic abscess 0 (0) 2 (3) 0.021
SIRS 3 (2) 4 (6) 0.073
Sepsis 14 (8) 9 (14) 0.183
Anastomotic leakage 31 (18) 8 (13) 0.295
Chylothorax 9 (5) 2 (3) 0.486
Intra-abdominal abscess 0 (0) 2 (3) 0.021
Renal failure 8 (5) 5 (8) 0.356
Liver failure 0 (0) 1 (2) 0.103
Deep venous thrombosis 2 (1) 0 (0) 0.385
Ileus 2 (1) 2 (3) 0.306
Minor complications
Wound infection 9 (5) 9 (14) 0.025
Wound dehiscence 3 (2) 2 (3) 0.522
Urinary tract infection 0 (0) 4 (6) 0.001
Reoperation 17 (10) 12 (19) 0.064
Mean time in operating
room (h)
6.1 6.3 0.384
Mean length of stay in ICU
(d)
2.5 5.0 \0.001
Mean hospital stay (d) 21.0 27.0 0.014
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The operation time, with a median of 6 hours, was not
different in both groups (95% CI, -0.72 to 0.28;
P = 0.384). The median ICU stay was 3 days, with a range
of 1–64 days. In group II, the ICU stay was signiﬁcantly
longer, with a median of 7 days (range, 1–64 days) versus
group I, with a median of 3 days (range, 1–56 days) (95%
CI, -9.95 to -1.86; P = 0.005). Reoperation was needed
in 29 patients as a result of complications, including
anastomotic leakage, postoperative bleeding, subphrenic
abscess, and obstructive ileus based on torsion at the
jejunostomy site. The median hospital stay was 22 days,
with 21 days in group I and 26 days in group II (95% CI,
-11.03 to 0.17; P = 0.06).
Long-Term Outcome
Median follow-up was 26 months (range, 0 to
199 months), and no patients were lost to follow-up. Fol-
low-up time was not different between the groups
(P = 0.701).
Stage of disease had no impact on survival between the
two groups (stage I, P = 0.298; stage II; P = 0.834; stage
III; P = 0.184; stage IVa; P = 2.09).
None of the individual complications had a statistically
signiﬁcant impact on survival. Overall, complications had
no inﬂuence on long-term survival, including postoperative
mortality (P = 0.174), and mortality (P = 0.655).
Recurrent disease occurred in 126 patients (54%): 99
patients (58%) in group I and 27 (42%) in group II
(P = 0.028). Time to development of recurrent disease did
not differ between the groups (P = 0.223).
For all 234 patients, including patients with postopera-
tive mortality, the 1-year survival was 74% and the 5-year
survival was 33%. There was no difference in survival
between the two groups (P = 0.535), with a 1-year sur-
vival of 76% in group I versus 70% in group II (P = 0.282)
and a 5-year survival of 33% in group I versus 33% in
group II (P = 0.676) (Fig. 1).
Age classiﬁcation of \70 and C70 years did not have
any prognostic value for survival (OR, 1.117; 95% CI,
0.787 to 1.584; P = 0.535). Also, increasing age as con-
tinuous variable did not have a prognostic value for worse
survival (OR, 1.005; 95% CI, 0.990 to 1.021; P = 0.514).
Cancer-related 5-year survival in patients without post-
operative mortality (n = 219) and cancer-related cause of
death was 35% and did not differ between the groups (35
vs. 37%, P = 0.874).
TABLE 3 Prognostic value of advanced age on development of
complications in patients with esophageal cancer
Variable Odds ratio 95% CI P value
Overall complications 1.578 0.857–2.904 0.143
Pulmonary complications 1.750 0.980–3.126 0.050
Respiratory insufﬁciency 2.085 1.135–3.832 0.018
ARDS 2.041 0.444–9.383 0.359
Pneumonia 1.552 0.766–3.146 0.222
Atelectasis 2.501 1.242–5.037 0.010
Pleural effusion 2.098 1.043–4.218 0.038
Empyema 1.575 0.658–3.770 0.308
Pulmonary embolism 2.041 0.444–9.383 0.359
Cardiac complications 3.178 1.655–6.100 0.001
Arrhythmia 2.971 1.542–5.723 0.001
Myocardial infarction 1.333 0.119–14.962 0.816
Other major complications
Rebleeding 2.767 0.671–11.412 0.159
Subphrenic abscess np
SIRS 3.711 0.807–17.066 0.092
Sepsis 1.823 0.187
Anastomotic leakage 0.641 0.747–4.449 0.297
Chylothorax 0.577 0.277–1.479 0.490
Intra-abdominal abscess np
Renal failure 1.716 0.121–2.746 0.360
Liver failure np
Deep venous thrombosis np
Ileus 2.710 0.540–5.455 0.324
Minor complications 0.374–19.655
Wound infection 2.927 1.106–7.748 0.031
Wound dehiscence 1.796 0.293–11.003 0.527
Urinary tract infection np
95% CI, 95% conﬁdence interval; ARDS, acute respiratory distress
syndrome; SIRS, systemic inﬂammatory response syndrome; np, not
enough statistical power
Bold values are signiﬁcant (P B 0.005)
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FIG. 1 Kaplan–Meier overall survival curve (n = 234) of patients in
group I (age\70 years) and group II (age C 70 years) (n = 170 vs.
n = 64, P = 0.535), including postoperative mortality
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difference between the two groups (P = 0.135). In group I
and II separately, there was no statistical difference in
survival of patients with and without comorbidity (Fig. 2a,
b), although there was a trend for worse survival in elderly
patients with comorbidity (P = 0.087) (Fig. 2b).
The presence of comorbidity was an independent prog-
nostic factor for long-term survival (OR, 1.679; 95% CI,
1.219 to 2.314; P = 0.002). The Kaplan-Meier curve
showed signiﬁcantly better survival for patients without
comorbidity in the long term (P = 0.001) (Fig. 3).
DISCUSSION
By applying a thoracotomy-based operative approach
with extensive two-ﬁeld lymph node dissection for
esophageal cancer, we were able to effectuate a 5-year
cancer-speciﬁc survival rate of 35% in a patient population
with 49% stage III and IV disease, regardless of age and
comorbidity.
The median hospital stay was comparable with reported
numbers in literature.
12 Hospital stay is relatively long
because some patients with comorbidity in this relatively
elderly population needed extensive preoperative workup.
Moreover, in our hospital, most patients with anastomotic
leakage are usually treated conservatively with good
results.
Advanced age (C70 years) had no statistically signiﬁ-
cant inﬂuence on mortality after extended esophagectomy,
even though there was a nonstatistical trend of a higher
postoperative mortality. Overall, elderly patients had no
higher postoperative complication rate than the younger
group. However, cardiac complications in particular
arrhythmia, and pulmonary complications, especially
respiratory insufﬁciency, atelectasis, and pleural effusion,
occurred more frequently in elderly patients. Age
C70 years was not a prognostic factor for development of
postoperative complications. Furthermore, the occurrence
of complications did not lead to a decreased survival. On
the other hand, comorbidity was the strongest prognostic
factor for the development of complications. In this study,
cardiovascular comorbidity in the elderly subgroup had a
negative effect on postoperative mortality. Because of this
relatively small-sized subgroup, it is difﬁcult to give spe-
ciﬁc recommendations.
Compared with patients\70 years old, recurrent disease
was statistically signiﬁcant lower in the elderly group. But
the higher number of cardiopulmonary complications and
the trend for a higher postoperative mortality in the elderly
is concerning.
Along with a general increase of incidence of esopha-
geal adenocarcinoma, there is a rising incidence in
esophageal cancer in elderly patients—up to 600% in the
1.0
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8 0 1 0
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p = 0.472
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Age ≥70 years
p = 0.087
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b
FIG. 2 a Kaplan–Meier survival curve of patients in group I
(age\70 years) with preoperative comorbidity and those without
(n = 65 vs. n = 105, P = 0.472). b Kaplan–Meier survival curve of
patients in group II (age C 70 years) with preoperative comorbidity
and those without (n = 32 vs. n = 32, P = 0.087)
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FIG. 3 Kaplan–Meier survival curve of patients with preoperative
comorbidity and those without, regardless of age (n = 97 vs.
n = 137, P = 0.001)
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26 Advances in treatment of esophageal cancer
surgery have been remarkable; improved staging modali-
ties, perioperative management, surgical techniques, and
postoperative care have reduced postoperative mortality
and morbidity rates and have enhanced better survival.
Moreover, improvements in postoperative complications in
the elderly have been reported.
19
Our results reﬂect the improvement in overall outcomes
after esophagectomy for cancer over the last 10 years and
demonstrate that this improvement in short-term outcome
is evident in the elderly population.
20 Several studies
reported worse postoperative course in the elderly patients,
with a high mortality rate and a decreased overall long-
term survival with increasing age.
20,22 More recent studies
showed acceptable results regarding mortality and survival
because of better surgical techniques, centralization, and
more intensive perioperative care.
8,10–12,16–19,21,27 There-
fore, some studies focus on even older patients ([75 or
[80 years).
9,12,16
Preoperative risk assessment and estimation of prog-
nostic risk factors in the elderly remain controversial.
Some studies found a strong association between high age
and increased risk of worse prognosis during and after
esophagectomy.
7,28 Particularly cardiac and pulmonary
complications occur more frequently in the high age
groups.
8,16,19,28 However, reliable individual risk analysis
stratiﬁcation for individual elderly patients is lacking. This
is mainly due to a reluctance to enroll elderly patients in
clinical trials, which we think is not appropriate.
29 This is
of importance because the elderly have more cardiopul-
monary complications, which complicate the postoperative
course. More research is needed for adequate scoring sys-
tems identifying the elderly at risk for pulmonary and
cardiac complications.
8,16,19,28 This may permit preopera-
tive intervention such as cardiac and pulmonary support
that can reduce the risk of postoperative complications.
12
In the literature, a discussion is ongoing on the type of
surgery required for elderly patients. Some surgeons
advocate a limited resection in cases of postoperative
complications and coexisting disease in the elderly. How-
ever, transthoracic esophagectomy with two-ﬁeld lymph
node dissection is not associated with increased mortality
or reduced long-term survival in the elderly population.
20
In this study, there was a higher mortality rate in the
elderly, although it was not statistically signiﬁcant, but
elderly patients had equally long-term survival after sur-
gery. Further optimization in selection criteria and risk
stratiﬁcation for the elderly will better clarify the supposed
advantage of extended esophagectomy. Hence, we recom-
mend thorough preoperative assessment in all patients. A
threshold to deny surgery on the basis of age alone seems
unreasonable in this patient group because of large differ-
ences in comorbidity and clinical manifestations of cancer.
A larger study group might strengthen the nonstatistical
trends on postoperative mortality in this study, suggesting
the need for a large prospective study. The choice to
operate on elderly patients with comorbidity remains dif-
ﬁcult, but the consequences of not operating may result in
an even greater dilemma. The strength of this study is the
careful selection of patients for surgery, the homogeneous
groups for comparison, and the complete follow-up. It
quantiﬁes what the risk is in an experienced center.
More attention is needed in prospective clinical trials for
elderly patients, further improving postoperative course
and long-term survival. Furthermore, individual risk-anal-
ysis stratiﬁcation should be developed with a focus on
patients with comorbidity. Centralization and more inten-
sive perioperative care for elderly patients are needed. Our
data support the view that esophageal resection within
centralized organized care with a coordinated multidisci-
plinary approach and multidisciplinary teamwork is
feasible and appropriate for all reasonably ﬁt patients,
regardless of age. The increased use of neoadjuvant therapy
in the elderly patients is needed, especially in clinical trials,
with the perception that individualization of treatment will
be the future standard. A subdivision based solely on age
is undesirable. Elderly patients with no preoperative risk
factors may be more readily tolerate chemoradiotherapy
and surgery than younger patients with comorbidity.
In conclusion, the increasing life expectancy in the gen-
eral population will lead to a further increasing incidence of
elderly patients with esophageal cancer in the near future.
Therefore, more attention is needed for the treatment of the
elderly patients. Because this study showed no difference in
short- and long-term survival for the elderly group, and
elderly patients did not have a substantially worse postop-
erative course, radical resection should not be withheld in
elderly patients. Although age alone is not a prognostic
indicator for survival in patients who undergo esophagec-
tomy for cancer, comorbidity at any age might be.
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